Tartaric Acid
Apexbio Technology LLC ENMD-2076 934353-76-1 200mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 L-(+)-Tartaric acid 1291074-87-7 5mg
ENMD-2076 L- plus -Tartaric acid is a small-molecule inhibitor targeting Aurora kinase A and B It is designed to inhibit the activity of these kinases thereby regulating cell cycle progression and mitotic processes ENMD-2076 L- plus -Tartaric acid exerts its biological activity primarily through the inhibition of Aurora kinase A and B with IC50 values of approximately 14 nM and 350 nM respectively In cell-based studies ENMD-2076 inhibits various breast cancer cell lines suppresses colony formation and induces G2 phase cell-cycle arrest Based on these pharmacological properties ENMD-2076 L- plus -Tartaric acid holds research potential in breast and hematological malignancies
Apexbio Technology LLC ENMD-2076 934353-76-1 5mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Medchemexpress LLC HY-N2522 5mg Medchemexpress, Carboxyatractyloside (dipotassium) CAS:33286-30-5 Purity:>98%
Medchemexpress, HY-N2522 5mg Carboxyatractyloside (dipotassium) CAS:33286-30-5 Carboxyatractyloside dipotassium is a toxic natural product, acts as an inhibitor of ADP/ATP carrier, inhibits mitochondrial ADP/ATP transport. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
eMolecules (+)-Diacetyl-d-tartaric acid | 66749-60-8 | MFCD02093460 | 1g
Combi-Blocks | (+)-Diacetyl-d-tartaric acid | 1g | 495744747 | QG-6219 | 95.000 | 66749-60-8 | MFCD02093460 | 234.160 | C8H10O8
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Sigma Organic Chemistry DL-Tartaric acid | 25G | 133-37-9 | MFCD00071626
DL-Tartaric acid , 25G
About this item:
CAS #: 133-37-9
MDL #: MFCD00071626
Purity: 99%
Chemical Formula: C4H6O6
Molecular Weight: 150.09
UNSPSC Code: 12352100
Sigma Organic Chemistry meso-Tartaric acid mono | 25G | 5990-63-6 | MFCD00150742
meso-Tartaric acid mono , 25G
About this item:
CAS #: 5990-63-6
MDL #: MFCD00150742
Purity: ≥97
Molecular Weight: 168.1
UNSPSC Code: 12352100
Sigma Organic Chemistry (+)-2,3-Dibenzoyl-D-tartaric acid | 250G | 17026-42-5 | MFCD00063222 | >=99.0% (T)
(+)-2,3-Dibenzoyl-D-tartaric acid | 250G | 17026-42-5 | MFCD00063222 | >=99.0% (T)
Selleck Chemical LLC ENMD-2076 S1181-1g
ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1 86 nM 25-fold selective for Aurora A than over Aurora B and less potent to RET SRC NTRK1/TRKA CSF1R/FMS VEGFR2/KDR FGFR and PDGFR ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0 025 to 0 7 M which induces apoptosis and G2/M phase arrest Phase 2
Chem-Impex International, Inc. (-)-Dibenzoyl-L-tartaric acid | MFCD00003074 | 25G
(-)-Dibenzoyl-L-tartaric acid, MFCD00003074, 25G
Chem-Impex International, Inc. D(-)-Tartaric acid | 147-71-7 | MFCD00004238 | 100G
D(-)-Tartaric acid, 147-71-7, MFCD00004238, 100G
Chem-Impex International, Inc. (+)-O,O'-Di-p-toluoyl-D-tartaric acid | 32634-68-7 | MFCD00008552 | 100G
(+)-O,O'-Di-p-toluoyl-D-tartaric acid, 32634-68-7, MFCD00008552, 100G
Sigma Aldrich Fine Chemicals Biosciences Sodium tartrate dibasic dihydrate BioXtra, >=99.0% | 6106-24-7 | MFCD00150035 | 500G
Sodium tartrate dibasic dihydrate BioXtra, >=99.0% | Purity: >=99.0% | Mol Wt: 230.08 | 6106-24-7 | MFCD00150035 | 500G
Apexbio Technology LLC ENMD-2076 934353-76-1 50mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 10mM (in 1mL DMSO)
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies